{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"CTXR","limit":50},"count":50,"signals":[{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":44,"context":"roles of Chief Executive Officer and Chairman should be separate and, if they are to be separate, whether the Chairman should be selected from the non-employee directors or be an employee. Our Board appointed Leonard Mazur as our Chief Executive Officer and Executive Chairman, Myron Holubiak as our Executive Vice Chairman of the Board, and Suren Dutia as Lead Independent Director. **** There are no family relationships among our ex","filed_date":"2026-02-24","accession":"0001213900-26-019566","full_text":"https://origin.rootz.global/static/filing/0001213900-26-019566.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":36,"context":"Officer since November 2017, upon the acquisition of LMB by the Company. From April 1, 2014 until November 2017, Mr. Bartushak served as Chief Financial Officer of LMB. In November 2022, he was also appointed Chief Business Officer of the Company. Mr. Bartushak also serves as Treasurer and Chief Financial Officer of our majority-owned subsidiary, Citius Oncology. Mr. Bartushak is an experienced finance professional for early-st","filed_date":"2026-01-28","accession":"0001213900-26-008861","full_text":"https://origin.rootz.global/static/filing/0001213900-26-008861.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"uppliers purchase raw materials and supplies on the open market. Substantially all such materials are obtainable from a number of sources so that the loss of any one source of supply would not have a material adverse effect on us. Our product development and manufacturing for LYMPHIR is subject to regulation under various federal and state laws, including the Food, Drug and Cosmetic Act, Occupational Safety and Health A","filed_date":"2025-12-23","accession":"0001213900-25-125333","full_text":"https://origin.rootz.global/static/filing/0001213900-25-125333.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":46,"context":"our executive officers is designed to enable us to attract and retain talented and experienced senior executives to lead our company successfully in a competitive environment. The compensation of the Named Executive Officers is described on pages 23-34 of this proxy statement. We are asking stockholders to vote on the following resolution: **RESOLVED**, that the stockholders of Citius Pharmaceuticals, Inc. approve,on an","filed_date":"2025-01-27","accession":"0001213900-25-006984","full_text":"https://origin.rootz.global/static/filing/0001213900-25-006984.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"nt in new or complementary businesses, products or technologies, and the failure to manage these acquisitions or investments, or the failure to integrate them with our existing business, could have a material adverse effect on us. | | |  | Conflicts of interest may arise from our relationships with Citius Oncology and NoveCite. | | |  | We might not obtain the necessary U.S. or foreign regulatory approvals to commercial","filed_date":"2024-12-27","accession":"0001213900-24-113149","full_text":"https://origin.rootz.global/static/filing/0001213900-24-113149.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":43,"context":"ef Executive Officer and Chairman should be separate and, if they are to be separate, whether the Chairman should be selected from the non-employee directors or be an employee. Our Board of Directors appointed Leonard Mazur as our Chief Executive Officer and Executive Chairman, Myron Holubiak as our Executive Vice Chairman of the Board, and Suren Dutia as Lead Independent Director. ** ** There are no family relationships among our e","filed_date":"2024-01-26","accession":"0001213900-24-006971","full_text":"https://origin.rootz.global/static/filing/0001213900-24-006971.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"nt in new or complementary businesses, products or technologies, and the failure to manage these acquisitions or investments, or the failure to integrate them with our existing business, could have a material adverse effect on us. |  | |  | | We might not obtain the necessary U.S. or foreign regulatory approvals to commercialize any product candidates. |  | |  | | Following any regulatory approval of any product candida","filed_date":"2023-12-29","accession":"0001213900-23-099889","full_text":"https://origin.rootz.global/static/filing/0001213900-23-099889.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":45,"context":"ef Executive Officer and Chairman should be separate and, if they are to be separate, whether the Chairman should be selected from the non-employee directors or be an employee. Our Board of Directors appointed Leonard Mazur as our Chief Executive Officer and Executive Chairman, and Myron Holubiak as our Executive Vice Chairman of the Board. ** ** There are no family relationships among our executive officers and directors or directo","filed_date":"2022-12-22","accession":"0001213900-22-082224","full_text":"https://origin.rootz.global/static/filing/0001213900-22-082224.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"versely affect our clinical trial operations in the future, which could increase our operating expenses and the length of time to complete the Mino-Lok Phase 3 trial and any/or other trial and have a material adverse effect on our financial results. | | |  |  |  We cannot assure you that we will receive the approvals necessary to commercialize for sale any product candidates we are currently developing or that we may ac","filed_date":"2022-12-22","accession":"0001213900-22-082217","full_text":"https://origin.rootz.global/static/filing/0001213900-22-082217.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":38,"context":"ve on a non-binding advisory basis our executive compensation, (iii) recommend, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation, and (iv) ratify the selection of the independent auditors for the fiscal year ending September 30, 2022. The presence, in person or by properly executed proxy, of the holders of shares","filed_date":"2021-12-20","accession":"0001213900-21-066329","full_text":"https://origin.rootz.global/static/filing/0001213900-21-066329.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"Phase 3 trial and may materially and adversely affect our clinical trial operations in the future, which could increase our operating expenses and the length of time to complete the trial and have a material adverse effect on our financial results. | | |  |  |  We cannot assure you that we will receive the approvals necessary to commercialize for sale any product candidates we are currently developing or that we may ac","filed_date":"2021-12-15","accession":"0001213900-21-065464","full_text":"https://origin.rootz.global/static/filing/0001213900-21-065464.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"ef Executive Officer and Chairman should be separate and, if they are to be separate, whether the Chairman should be selected from the non-employee directors or be an employee. Our Board of Directors appointed Myron Holubiak as our Chief Executive Officer and Leonard Mazur as the Executive Chairman of the Board. ** ** There are no family relationships among our executive officers and directors. ** ** **Selection of Nominees for our B","filed_date":"2020-12-21","accession":"0001213900-20-043792","full_text":"https://origin.rootz.global/static/filing/0001213900-20-043792.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"Phase 3 trial and may materially and adversely affect our clinical trial operations in the future, which could increase our operating expenses and the length of time to complete the trial and have a material adverse effect on our financial results. | | |  | | We cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates that are under development and we cannot, therefore,","filed_date":"2020-12-16","accession":"0001213900-20-043004","full_text":"https://origin.rootz.global/static/filing/0001213900-20-043004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":6,"context":"re to COVID-19, which could further negatively impact the Mino-Lok trial. In addition, if the FDA elects to delay face-to-face meetings for an extended period of time due to COVID-19, it could have a material adverse effect on our Mino-Lok trial and our other product candidates. Any or all of these events could increase our operating expenses and the length of time to complete the trial and have a material adverse effec","filed_date":"2020-06-05","accession":"0001213900-20-014231","full_text":"https://origin.rootz.global/static/filing/0001213900-20-014231.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":40,"context":"term covered employee includes the Companys chief executive officer and the two other most highly compensated executive officers who are required to be disclosed in the Companys proxy statement as a named executive officer based on the amount of their total compensation. Certain compensation, including compensation paid based on the achievement of pre-established performance goals, is excluded from this deduction limit","filed_date":"2019-12-20","accession":"0001213900-19-026703","full_text":"https://origin.rootz.global/static/filing/0001213900-19-026703.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":7,"context":"uppliers purchase raw materials and supplies on the open market. Substantially all such materials are obtainable from a number of sources so that the loss of any one source of supply would not have a material adverse effect on us. If we elect to conduct product development and manufacturing, we will be subject to regulation under various federal and state laws, including the Occupational Safety and Health Act, the Envir","filed_date":"2019-12-16","accession":"0001213900-19-026259","full_text":"https://origin.rootz.global/static/filing/0001213900-19-026259.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":39,"context":"our executive officers is designed to enable us to attract and retain talented and experienced senior executives to lead our company successfully in a competitive environment. The compensation of the Named Executive Officers is described on pages 17-23 of this proxy statement. We are asking stockholders to vote on the following resolution: **RESOLVED**, that the stockholders of Citius Pharmaceuticals, Inc. approve, on a","filed_date":"2018-12-20","accession":"0001213900-18-017613","full_text":"https://origin.rootz.global/static/filing/0001213900-18-017613.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":7,"context":"uppliers purchase raw materials and supplies on the open market. Substantially all such materials are obtainable from a number of sources so that the loss of any one source of supply would not have a material adverse effect on us. If we elect to conduct product development and manufacturing, we will be subject to regulation under various federal and state laws, including the Occupational Safety and Health Act, the Envir","filed_date":"2018-12-11","accession":"0001213900-18-017214","full_text":"https://origin.rootz.global/static/filing/0001213900-18-017214.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":6,"context":"uppliers purchase raw materials and supplies on the open market. Substantially all such materials are obtainable from a number of sources so that the loss of any one source of supply would not have a material adverse effect on us. If we elect to conduct product development and manufacturing, we will be subject to regulation under various federal and state laws, including the Occupational Safety and Health Act, the Envir","filed_date":"2017-12-13","accession":"0001213900-17-013191","full_text":"https://origin.rootz.global/static/filing/0001213900-17-013191.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":5,"context":"uppliers purchase raw materials and supplies on the open market. Substantially all such materials are obtainable from a number of sources so that the loss of any one source of supply would not have a material adverse effect on us.  | | | | 10 | | | | | | | | Table of Contents | | If we elect to conduct product development and manufacturing, we will be subject to regulation under various federal and state laws, including","filed_date":"2016-12-23","accession":"0001477932-16-014315","full_text":"https://origin.rootz.global/static/filing/0001477932-16-014315.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"f approximately $7.0 million from our private placement offerings through fiscal year 2016. Additionally, in connection with the acquisition of LMB our Executive Chairman Leonard Mazur made an equity investment of $3.0 million in March 2016. Additionally, Leonard Mazur has loaned the Company $1,150,000 in the form of demand promissory notes. We may need to seek additional financing, including from affiliates, to continue o","filed_date":"2016-12-23","accession":"0001477932-16-014315","full_text":"https://origin.rootz.global/static/filing/0001477932-16-014315.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"017, with the exact ratio to be set at a whole number within this range as determined by the Board of Directors; | | | | | | | 5. | To approve, on an advisory basis, the compensation of the Company's named executive officers; | | | | | | | 6. | To recommend, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation; | | |","filed_date":"2016-08-11","accession":"0001477932-16-011779","full_text":"https://origin.rootz.global/static/filing/0001477932-16-011779.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":85,"match_count":10,"context":"not a candidate at the time the election occurs, such proxy will be voted for the election of another nominee to be designated by the Board to fill any such vacancy. The term of office of each person elected as a director will continue until the next annual meeting or until his or her successor has been elected and qualified, or until the directors death, resignation or removal. Biographical and certain other informat","filed_date":"2017-12-13","accession":"0001213900-17-013195","full_text":"https://origin.rootz.global/static/filing/0001213900-17-013195.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":85,"match_count":5,"context":"uppliers purchase raw materials and supplies on the open market. Substantially all such materials are obtainable from a number of sources so that the loss of any one source of supply would not have a material adverse effect on us. We have entered into a supply agreement with Alpex pursuant to which Alpex supplies us with the active pharmaceutical ingredient, or API, for phentermine hydrochloride. Alpex currently has one","filed_date":"2015-12-14","accession":"0001477932-15-007617","full_text":"https://origin.rootz.global/static/filing/0001477932-15-007617.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"with GAAP. Indenture means this Indenture as amended, restated or supplemented from time to time. 2 Interest Payment Date, when used with respect to any Security, means the Stated Maturity of an installment of interest on such Security. Lien means, with respect to any property or assets of any Person, any mortgage or deed of trust, pledge, hypothecation, assignment, deposit arrangement, security inte","filed_date":"2024-02-23","accession":"0001213900-24-016515","full_text":"https://origin.rootz.global/static/filing/0001213900-24-016515.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":72,"match_count":9,"context":"eir 2013, 2014 and 2015 tax returns. Tax years subsequent to 2011 are subject to examination by federal and state authorities.  **12. SUBSEQUENT EVENTS** On October 1 and October 8, 2015, the Company appointed two new directors. Each director received an option to purchase 400,000 shares of the Company's common stock at an exercise price of $0.54 per share in consideration for their services as members of the Company's boa","filed_date":"2015-12-14","accession":"0001477932-15-007617","full_text":"https://origin.rootz.global/static/filing/0001477932-15-007617.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":71,"match_count":2,"context":"| **PART II - OTHER INFORMATION** **Item 1. Legal Proceedings** None. **Item 1A. Risk Factors** Our business is subject to numerous risks. The following important factors, among others, could have a material adverse effect on our business, financial condition or results of operations.  **Citius has a history of net losses and expects to incur losses for the foreseeable future. We may never generate revenues or, if we a","filed_date":"2017-08-14","accession":"0001477932-17-003946","full_text":"https://origin.rootz.global/static/filing/0001477932-17-003946.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":66,"match_count":7,"context":"the Companys ability to obtain additional financing and the Companys compliance with governmental and other regulations. **I/ONTAK** **Overview** In September 2021, the Company announced that it had entered into a definitive agreement with Dr. Reddys Laboratories SA, a subsidiary of Dr. Reddys Laboratories, Ltd. (collectively, Dr. Reddys), to acquire its exclusive license of E7777 (denileukin diftitox), a late-stage oncology immun","filed_date":"2022-12-22","accession":"0001213900-22-082217","full_text":"https://origin.rootz.global/static/filing/0001213900-22-082217.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":58,"match_count":6,"context":"ely $14.6 million from our public and private placement offerings through September 2017. Additionally, in connection with the acquisition of LMB our Executive Chairman, Leonard Mazur, made an equity investment of $3.0 million in March 2016. Mr. Mazur has also loaned the Company $4,710,000 pursuant to convertible promissory notes. On August 8, 2017, these notes and accrued interest of $76,240 were converted into 1,547,067","filed_date":"2017-12-13","accession":"0001213900-17-013191","full_text":"https://origin.rootz.global/static/filing/0001213900-17-013191.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":57,"match_count":4,"context":"cash requirements of implementing our business strategies will be available on acceptable terms.The inability of Trail One to gain access to capital markets or obtain acceptable financing will have a material adverse effect upon the results of its operations and its financial conditions.The proceeds from the sale of the securities offered in this registration statement will go directly to the selling security holder and","filed_date":"2012-01-13","accession":"0001185185-12-000067","full_text":"https://origin.rootz.global/static/filing/0001185185-12-000067.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"-oncology combination therapy. A Phase 1 trial was initiated in June 2021 at the University of Minnesota, Masonic Cancer Center. This study is a single-arm open-label trial which has an estimated enrollment of 20 participants who will be administered denileukin diftitox prior to Chimeric Antigen Receptor, (CAR-T) therapies. The Phase 1 study consists of two components: dose finding to establish a max","filed_date":"2024-12-27","accession":"0001213900-24-113149","full_text":"https://origin.rootz.global/static/filing/0001213900-24-113149.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"each person or group as those terms are used in Section 13(d)(3) of the Exchange Act believed by us to beneficially own more than 5% of our common stock, (ii) each of our directors, (iii) each of our named executive officers, and (iv) all of our directors and named executive officers as a group. Except as otherwise noted, each person named in the table has sole voting and investment power with respect to all shares show","filed_date":"2021-04-12","accession":"0001213900-21-021181","full_text":"https://origin.rootz.global/static/filing/0001213900-21-021181.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":55,"match_count":5,"context":"of consultants to support our clinical studies and manufacturing efforts. **Executive Officers of Citius Pharma** **Leonard Mazur**, Chief Executive Officer, Chairman and Secretary Mr. Mazur, 80, was appointed Chief Executive Officer effective May 1, 2022, and has been a member of the Board since September 2014. Mr. Mazur previously served as Chief Executive Officer, President, and Chief Operating Officer from September 2014 unti","filed_date":"2025-12-23","accession":"0001213900-25-125333","full_text":"https://origin.rootz.global/static/filing/0001213900-25-125333.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":55,"match_count":5,"context":"of consultants to support our clinical studies and manufacturing efforts. **Executive Officers of Citius Pharma** **Leonard Mazur**, Chief Executive Officer, Chairman and Secretary Mr. Mazur, 79, was appointed Chief Executive Officer effective May 1, 2022, and has been a member of the Board since September 2014. Mr. Mazur previously served as Chief Executive Officer, President, and Chief Operating Officer from September 2014 unti","filed_date":"2024-12-27","accession":"0001213900-24-113149","full_text":"https://origin.rootz.global/static/filing/0001213900-24-113149.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":52,"match_count":4,"context":"cash requirements of implementing our business strategies will be available on acceptable terms.The inability of Trail One to gain access to capital markets or obtain acceptable financing will have a material adverse effect upon the results of its operations and its financial conditions.The proceeds from the sale of the securities offered in this registration statement will go directly to the selling security holder and","filed_date":"2013-01-15","accession":"0001185185-13-000090","full_text":"https://origin.rootz.global/static/filing/0001185185-13-000090.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":52,"match_count":4,"context":"l be available on acceptable terms, or at all. If the Company is unable to raise sufficient capital, find strategic partners or generate substantial revenue from the sale of LYMPHIR, there would be a material adverse effect on its business. Further, the Company expects in the future to incur additional expenses as it continues to develop its product candidates, including seeking regulatory approval, and protecting its i","filed_date":"2026-08-14","accession":"0001213900-26-090185","full_text":"https://origin.rootz.global/static/filing/0001213900-26-090185.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":50,"match_count":5,"context":"e involving the original cell line included in the licensed technology, then Licensor shall remit to NoveCite 50% of such revenue. 58 **LYMPHIR**- In September 2021, the Company announced that it had entered into a definitive agreement with Dr. Reddys to acquire its exclusive license of E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma. Citius Pharma subs","filed_date":"2023-12-29","accession":"0001213900-23-099889","full_text":"https://origin.rootz.global/static/filing/0001213900-23-099889.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":50,"match_count":5,"context":"the Companys ability to obtain additional financing and the Companys compliance with governmental and other regulations. **I/ONTAK** **Overview** In September 2021, the Company announced that it had entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, \"Dr. Reddy's\"), to acquire its exclusive license of E7777 (denileukin diftitox), a late-stage oncology","filed_date":"2021-12-15","accession":"0001213900-21-065464","full_text":"https://origin.rootz.global/static/filing/0001213900-21-065464.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":50,"match_count":5,"context":"$70.5 million from our public and private placement offerings through September 30, 2020. Additionally, in connection with the acquisition of LMB our Executive Chairman, Leonard Mazur, made an equity investment of $3.0 million in March 2016. Mr. Mazur has also loaned us $4,710,000 pursuant to convertible promissory notes. On August 8, 2017, these notes and accrued interest of $76,240 were converted into 1,547,067 shares of","filed_date":"2020-12-16","accession":"0001213900-20-043004","full_text":"https://origin.rootz.global/static/filing/0001213900-20-043004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"-oncology combination therapy. A Phase 1 trial was initiated in June 2021 at the University of Minnesota, Masonic Cancer Center. This study is a single-arm open-label trial which has an estimated enrollment of 20 participants who will be administered denileukin diftitox prior to Chimeric Antigen Receptor (CAR-T) therapies. The Phase 1 study consists of two components: dose finding to establish a maxi","filed_date":"2025-12-23","accession":"0001213900-25-125333","full_text":"https://origin.rootz.global/static/filing/0001213900-25-125333.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"PRESS RELEASE, DATED JANUARY 2, 2024 **Exhibit 99.1** **Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update** Mino-Lok Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR BLA resubmission on track for early 2024 **CRANFORD, N.J.**, January 2, 2024 -- Citius Pharmaceuticals, Inc. (Citius or the Company) (Nasdaq: CTXR)","filed_date":"2024-01-02","accession":"0001213900-24-000247","full_text":"https://origin.rootz.global/static/filing/0001213900-24-000247.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"-oncology combination therapy. A Phase 1 trial was initiated in June 2021 at the University of Minnesota, Masonic Cancer Center. This study is a single-arm open-label trial which has an estimated enrollment of 20 participants who will be administered denileukin diftitox prior to Chimeric Antigen Receptor, (CAR-T) therapies. The Phase 1 study consists of two components: dose finding to establish a max","filed_date":"2023-12-29","accession":"0001213900-23-099889","full_text":"https://origin.rootz.global/static/filing/0001213900-23-099889.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"d the progress of virtually all clinical trials, including our own, the Company continues to make progress, albeit at a slower pace. The Mino-Lok pivotal Phase 3 trial is now expected to complete enrollment in the first half of 2021 and, prior to full enrollment, we also expect to conduct an interim analysis for efficacy and safety in the second half of 2020. For Mino-Wrap, we have been consulting wi","filed_date":"2020-05-12","accession":"0001213900-20-011769","full_text":"https://origin.rootz.global/static/filing/0001213900-20-011769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":47,"match_count":4,"context":"$47.9 million from our public and private placement offerings through September 30, 2019. Additionally, in connection with the acquisition of LMB our Executive Chairman, Leonard Mazur, made an equity investment of $3.0 million in March 2016. Mr. Mazur has also loaned us $4,710,000 pursuant to convertible promissory notes. On August 8, 2017, these notes and accrued interest of $76,240 were converted into 1,547,067 shares of","filed_date":"2019-12-16","accession":"0001213900-19-026259","full_text":"https://origin.rootz.global/static/filing/0001213900-19-026259.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":47,"match_count":4,"context":"$35.6 million from our public and private placement offerings through September 30, 2018. Additionally, in connection with the acquisition of LMB our Executive Chairman, Leonard Mazur, made an equity investment of $3.0 million in March 2016. Mr. Mazur has also loaned us $4,710,000 pursuant to convertible promissory notes. On August 8, 2017, these notes and accrued interest of $76,240 were converted into 1,547,067 shares of","filed_date":"2018-12-11","accession":"0001213900-18-017214","full_text":"https://origin.rootz.global/static/filing/0001213900-18-017214.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"ology combination therapy. A Phase 1 trial was initiated in June 2021 at the University of Minnesota, Masonic Cancer Center. This study is a single-arm non-randomized trial which has an estimated enrollment of 30 participants who will be administered E7777 prior to tisagenlecleucel Chimeric Antigen Receptor, (CAR-T) therapy. The Phase 1 study consists of two components: dose finding to establish a ma","filed_date":"2022-12-22","accession":"0001213900-22-082217","full_text":"https://origin.rootz.global/static/filing/0001213900-22-082217.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"cal Q3 2022 Business Highlights and Subsequent Developments** ** ** |  | - | Mino-Lok Phase 3 trial recruitment approached pre-Covid-19 pace; international trial sites engaged to accelerate trial enrollment; Company reiterates 92 failure events required for trial completion; | | |  | - | Halo-Lido Phase 2b trial initiated; enrollment completion anticipated by end of 2022; | | |  | - | I/ONTAK (denile","filed_date":"2022-08-11","accession":"0001213900-22-046925","full_text":"https://origin.rootz.global/static/filing/0001213900-22-046925.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"* ** *  **Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update** Mino-Lok Phase 3 trial expanded to include sites outside the U.S.; trial enrollment expected to be completed by end of 2022* * * *Topline results of Phase 3 trial in cancer immunotherapy I/ONTAK consistent with prior formulation; BLA submission on track for 2H 2022* * * *$55.8 mi","filed_date":"2022-05-12","accession":"0001213900-22-025988","full_text":"https://origin.rootz.global/static/filing/0001213900-22-025988.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"ection with the qualification of an alternate manufacturing facility). In addition, the License provides for Development Cost Reimbursement which Prenzamax shall pay to Citius in equal quarterly installments of $115,152 over the course of twelve Fiscal Quarters, starting with the first Fiscal Quarter after the Profitability Date. \"Profitability Date\" means the date on which four Profit Share Payments","filed_date":"2015-12-14","accession":"0001477932-15-007617","full_text":"https://origin.rootz.global/static/filing/0001477932-15-007617.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CTXR","company":"Citius Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":37,"match_count":4,"context":"tion 13(d)(3) of the Securities Exchange Act of 1934, as amended, (the Exchange Act) believed by us to beneficially own more than 5% of our common stock, (ii) each of our directors, (iii) each of our named executive officers, and (iv) all of our current directors and executive officers as a group. Except as otherwise noted, each person named in the table has sole voting and investment power with respect to all shares sh","filed_date":"2019-09-20","accession":"0001213900-19-018533","full_text":"https://origin.rootz.global/static/filing/0001213900-19-018533.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"502b056fdfdfdcd43cad5b433b12b508d60cf033ccc16a87c7173a39915fe696","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"245b84d454d6ac63d652be0e3ebd859500d9f13e4d9b78ce58230e2f24f2775c","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":455,"hourly_limit":500,"remaining":45,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}